Health
Regeneron suspends COVID-19 antibody trial among sickest patients – Gulf News
Move follows recommendation from independent committee which assesses results
A Regeneron Pharmaceuticals scientist works in the company’s Infectious disease lab in New York state on an experimental coronavirus antibody drug.
Image Credit: Regeneron / via AP file
Washington: US biotech firm Regeneron on Friday said it was suspending enrollment for a study of its COVID-19 antibody treatment among the sickest patients who require high-flow oxygen or are on ventilators.
The move follows a recommendation from an independent data monitoring committee (IDMC) which assesses the…
-
Business18 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business20 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
Business17 hours agoHere’s what analysts expect for the BHP share price in the coming year
-
General9 hours agoVictorian school teacher charged with soliciting child abuse material